Cancer patients appear to have a higher risk of COVID-19-related complications and mortality compared to the general population \[[@R1]--[@R10]\], due in part to factors such as older age, higher smoking rates, more comorbidities, frequent exposure to health care settings, and immunomodulatory effects of cancer therapies. In a multicenter study from Wuhan, China, patients with cancer hospitalized with COVID-19 infection were found to have higher rates of ICU admission, invasive ventilation, and severe symptoms when compared with age-matched non-cancer controls \[[@R9]\]. Similarly, in a New York City hospital system, admitted cancer patients were found to have higher risk of severe COVID-19 compared to non-cancer patients matched for age, sex, and comorbidities \[[@R11]\]. Additionally, recent administration of anti-cancer therapies has been associated with higher risk of mortality or complications from SARS-CoV-2 \[[@R7]--[@R12]\]. Because most studies have focused on cancer patients hospitalized with severe COVID-19, it is unclear whether cancer status has an independent adverse impact on clinical outcomes in a health system population-based group of patients diagnosed with SARS-CoV-2 infection. We leveraged the Penn Medicine Biobank (PMBB) at the University of Pennsylvania, an academic biobank allowing access to electronic health record (EHR) data \[[@R13]\], to investigate whether patients with cancer had worse COVID-19 outcomes than non-cancer patients.

Patients had previously consented to enrollment in PMBB prior to the onset of the COVID-19 pandemic, and were subsequently found to have SARS-CoV-2 infection by reverse transcriptase polymerase chain reaction (RT-PCR). Patients were defined as having a cancer diagnosis if they met at least one of three criteria: 1) three ICD-10 billing codes for an invasive (non-secondary) cancer, 2) inclusion in the Penn Medicine Cancer Registry, 3) one visit within a cancer service line clinic. All cancer diagnoses were confirmed by manual chart review. Patient characteristics and clinical outcomes (hospitalization, ICU admission, and 30-day mortality) were extracted from the EHR and compared in patients with and without cancer. Separate multivariable logistic regressions were performed to estimate odds ratios (OR) and 95% confidence intervals (CI) for the association between cancer diagnosis and COVID-19 outcomes (hospitalization, ICU admission, and mortality in the 30 days following COVID-19 diagnosis), adjusted for potential confounders including demographic factors, smoking status, comorbidities, and socioeconomic status estimated by the national poverty index based on neighborhood mapping \[[@R14], [@R15]\]. Exploratory subgroup analyses were performed to investigate these associations among patients with active cancer (defined as either having metastatic disease and/or receiving cancer-directed systemic therapy, radiation therapy, or surgical resection in the two months prior to COVID-19 diagnosis) compared to non-cancer patients, as well as those with cancer in remission compared to non-cancer patients.

As of June 2020, of 4,816 patients previously enrolled in PMBB who had been tested for COVID-19, 323 (7.3%) had laboratory-confirmed SARS-CoV-2 infection. Of COVID-19-positive patients, 67 (20.7%) had a cancer diagnosis (80.6% with solid tumor malignancy; and 26.9% with active cancer). Compared to non-cancer patients, COVID-19-positive cancer patients were more likely to be older (62 vs 50 years, p\<0.001), male (53.7% vs 39.5%, p=0.035), and have a history of smoking (55.2% vs 35.%, p=0.003, [Table 1](#T1){ref-type="table"}). Notably, the proportion of Black patients was significantly higher in both cancer and non-cancer COVID-19-positive patients (65.7% and 64.1%, respectively), compared to all PMBB patients tested for SARS-CoV-2 (32.0%, p\<0.001).

Rates of hospitalization, ICU admission, and 30-day mortality were higher in patients with cancer compared to those without cancer (55.2% vs 28.9%, 25.4% vs 11.7%, 13.4% vs 1.6%, respectively) ([Table 2](#T2){ref-type="table"}). Older age, Black race, and number of comorbidities were significantly associated with increased odds of hospitalization and ICU admission (all p\<0.05). In fully adjusted models, cancer diagnosis was associated with statistically significantly increased odds of hospitalization (OR=2.16, 95% CI 1.12--4.18) and 30-day mortality (OR=5.67, 95% CI 1.49--21.59), and trend toward increased odds of ICU admission (OR=1.91, 95% CI 0.90--4.06). In exploratory subgroup analyses by cancer status (i.e. active vs. remission), adjusted associations with hospitalization, ICU admission, and 30-day mortality were strongest in the subgroup of patients with active cancer compared to non-cancer patients (adjusted OR 4.25, 3.28, and 28.8 respectively, all p\<0.01), suggesting that the association between cancer diagnosis and poor COVID-19 outcomes was driven primarily by patients with active cancer.

Concerns about risk of COVID-19 in cancer patients have led to alterations in cancer care such as treatment regimen modifications, delayed screening, decreased clinical trial enrollment, and increased telemedicine use \[[@R16]\] -- the potential effects of which on cancer outcomes are as of yet unknown, although models predict a negative impact on survival \[[@R17]\]. Prior studies investigating the association between cancer and COVID-19 outcomes have largely focused on hospitalized patients with severe COVID-19 disease, who may not be representative of the general population. In particular, studies utilizing non-random samples, of which hospitalized patients are a classic example, are prone to collider bias, which can induce spurious or distorted associations \[[@R18]\]. We studied COVID-19-positive patients identified from a large pre-existing biobank, which allowed more unbiased population sampling of cancer and non-cancer patients. Our finding that cancer patients with COVID-19 were more likely than non-cancer patients to experience hospitalization and death even after adjusting for patient-level factors supports the hypothesis that cancer is an independent risk factor for poor COVID-19 outcomes.

Our study had several limitations. Our sample size did not allow detailed subgroup analysis of different cancer types, which may confer non-uniform risk of severe COVID-19 \[[@R1], [@R5], [@R8]\]. Similarly, our cohort contained a relatively small number of patients with active cancer, which precluded analysis of the impact of different cancer therapies on COVID-19 outcomes. A prospective observational study of patients in a United Kingdom cancer center network did not find an association between cancer therapy type in the past four weeks and mortality \[[@R19]\]. Given the conflicting evidence on the impacts of active vs. non-active cancer status, cancer stage, and cancer therapies on COVID-19 prognosis, deeper investigation of these variables is needed \[[@R2], [@R5], [@R9], [@R10], [@R12], [@R19]\].

In conclusion, in our cohort of COVID-19-positive patients identified from a health system population-based academic biobank, a diagnosis of cancer was strongly and independently associated with poor COVID-19 clinical outcomes including hospitalization and 30-day mortality. Given that it is critically important that these patients engage with the healthcare system for optimal cancer-directed management, our results suggest that patients with cancer, particularly those receiving active treatment, should be among groups specifically targeted for COVID-19 mitigation and prevention strategies such as vaccination.
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###### 

Baseline Characteristics, Cancer vs Non-Cancer COVID-19-Positive Patients

                                     Cancer (N=67)   No cancer (N=256)   p-value[\*](#TFN1){ref-type="table-fn"}
  ---------------------------------- --------------- ------------------- -----------------------------------------
  Age                                62 (53--71)     50 (37--60)         \<0.001
  Race                                                                   
   White                             18 (26.9%)      74 (28.9%)          0.980
   Black                             44 (65.7%)      164 (64.1%)         
   Asian                             2 (3.0%)        5 (2.0%)            
   Other                             2 (3.0%)        8 (3.1%)            
   Unknown                           1 ( 1.5%)       5 (2.0%)            
  Gender                                                                 
   Female                            31 (46.3%)      155 (60.5%)         0.035
   Male                              36 (53.7%)      101 (39.5%)         
  Ever Smoker                        37 (55.2%)      90 (35.2%)          0.003
  National Poverty Percentile        91 (63--93)     91 (76.5--93)       0.290
  Comorbidities                                                          
   Hypertension                      38 (56.7%)      117 (45.7%)         0.110
   Diabetes                          22 (32.8%)      72 (28.1%)          0.450
   Obesity                           12 (17.9%)      76 (29.7%)          0.054
   Pulmonary disease                 14 (20.9%)      36 (14.1%)          0.170
   Mood disorders                    8 (11.9%)       37 (14.5%)          0.600
   Ischemic cardiovascular disease   11 (16.4%)      29 (11.3%)          0.260
   Immunodeficiency                  5 ( 7.5%)       11 ( 4.3%)          0.290
   Cerebrovascular disease           3 (4.5%)        8 (3.1%)            0.590

Wilcoxon rank-sum test for continuous outcomes; Pearson's chi-squared test for categorical outcomes

###### 

Event Rates and Odds Ratios of Clinical Outcome in Cancer vs Non-Cancer COVID-19-Positive Patients

  Outcome                                                 Patients with cancer   Patients without cancer
  ------------------------------------------------------- ---------------------- -------------------------
  Hospitalization                                                                
   Event rate                                             55.2%                  28.9%
   Unadjusted OR (95% CI)                                 3.03 (1.75 to 5.27)    Ref
   Adjusted OR[\*](#TFN2){ref-type="table-fn"} (95% CI)   2.16 (1.12to4.18)      Ref
  ICU Admission                                                                  
   Event rate                                             25.4%                  11.7%
   Unadjusted OR (95% CI)                                 2.56 (1.31 to 5.00)    Ref
   Adjusted OR[\*](#TFN2){ref-type="table-fn"} (95% CI)   1.91 (0.90 to 4.06)    Ref
  30-Day Mortality                                                               
   Event rate                                             13.4%                  1.6%
   Unadjusted OR (95% CI)                                 9.78 (2.91 to 32.85)   Ref
   Adjusted OR[\*](#TFN2){ref-type="table-fn"} (95% CI)   5.67 (1.49 to 21.59)   Ref

Adjusted for age, race, gender, socioeconomic status, smoking, comorbidities OR, odds ratio; CI, confidence interval; Ref, reference population; ICU, intensive care unit
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